Coluracetam (INN; development code BCI-540; formerly MKC-231) is a purported nootropic drug of the racetam family. It contains a chemical group that is a bioisostere of the Tacrine family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Qualifying Therapeutic Discovery Project Grants for the State of California, IRS.gov. Findings from phase IIa have suggested that it would be a potential medication for comorbidity MDD with generalized anxiety disorder (GAD). BrainCells Inc. Announces Results From Exploratory Phase 2a Trial of BCI-540 BrainCells Inc is currently out-licensing the drug for this purpose. BCI-540 (coluracetam) | BrainCells It may also have potential use in prevention and treatment of ischemia retinopathy and and optic nerve injury.
Coluracetam has been shown to reverse the loss of choline acetyltransferase production in the medial septal nucleus of rats exposed to phencyclidine (PCP), and is considered a potential therapeutic drug for schizophrenia.
|
|